Insulin glargine - Biologic Drug Details

Summary for insulin glargine

Tradenames:	4
High Confidence Patents:	3
Applicants:	4
BLAs:	7
Suppliers: see list	5
Recent Clinical Trials:	See clinical trials for insulin glargine
Drug Prices:	Drug price information for insulin glargine

Recent Clinical Trials for insulin glargine

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Eastern Virginia Medical School	PHASE4
Nanjing First Hospital, Nanjing Medical University	PHASE4
Changzhou No.2 People's Hospital	PHASE4

See all insulin glargine clinical trials

Pharmacology for insulin glargine

Established Pharmacologic Class	Insulin Analog
Chemical Structure	Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin glargine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin glargine Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	5,370,629	2013-10-13	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	5,509,905	2013-10-13	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	5,656,722	2014-09-12	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	BASAGLAR	insulin glargine	Injection	205692	5,618,913	2006-08-29	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	BASAGLAR	insulin glargine	Injection	205692	5,656,722	2014-09-12	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for insulin glargine Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	10,004,686	2033-06-12	Patent claims search
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	10,016,338	2036-12-20	Patent claims search
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	10,029,011	2030-11-11	Patent claims search
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	10,092,513	2034-04-01	Patent claims search
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	10,117,909	2036-11-01	Patent claims search

International Patents for insulin glargine

Country	Patent Number	Estimated Expiration
Canada	2108691
Switzerland	682806
Germany	59309472
European Patent Office	0581924
World Intellectual Property Organization (WIPO)	9316740

Supplementary Protection Certificates for insulin glargine

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C00214826/01	Switzerland		FORMER REPRESENTATIVE: E. BLUM AND CO. PATENTANWAELTE, CH
00C0023	France		PRODUCT NAME: INSULIN GLARGINE; NAT. REGISTRATION NO/DATE: EU/0/00/134/001 20000609; FIRST REGISTRATION: EU/1/00/134/001 20000609
SZ 34/2000	Austria		PRODUCT NAME: LANTUS - INSULIN GLARGIN
99C0044	Belgium		PRODUCT NAME: INSULIN-ASPART; NAT. REGISTRATION NO/DATE: EU/1/99/119/001 19990907; FIRST REGISTRATION: CH 55045 01 19990615
0091020-8 0090020-9	Sweden		PRODUCT NAME: LANTUS - INSULIN GLARGIN; REGISTRATION NO/DATE: EU/1/00/134/001 20000609

Last updated: June 25, 2026

Insulin Glargine Market Dynamics and Financial Trajectory (2024–2029): Pricing, Share Shifts, and Patent-Driven Risk

Insulin glargine is a mature insulin analog with a large installed base, shrinking unit pricing in most markets, and ongoing revenue defensiveness driven by line extensions (notably Toujeo), biosimilar substitution, and payer design. Financial trajectory is dominated by (1) biosimilar entry ramp and formulary uptake, (2) conversion between products (Lantus to Toujeo or to glargine biosimilars), (3) geographic patent estates and exclusivity cliffs, and (4) contracting dynamics tied to outcomes and total-cost-of-care.

Across major markets, the financial arc has already shifted from originator growth to volume protection, margin containment, and share defense. The next step-change occurs where glargine biosimilars reach broad automatic substitution and where reference pricing tightens after biosimilar launches.

How big is the insulin glargine market and what drives growth?

Insulin glargine is the biggest-selling basal insulin class globally in terms of revenue scale within insulin analogs. Growth is constrained by (1) diabetes incidence growth being partly offset by tighter dosing and guideline-driven shifts, (2) biosimilar price compression, and (3) payer utilization controls. Revenue growth increasingly depends less on new prescribers and more on conversion between basal products and on contract economics.

What are the main products in insulin glargine’s commercial portfolio?

Commercially, “insulin glargine” revenue is split across:

• Insulin glargine (100 U/mL) originator and biosimilars (commonly referenced as Lantus and follow-on glargine 100)
• Insulin glargine U-300 (Toujeo, 300 U/mL)
• Subsequent glargine biosimilars in each jurisdiction (naming and coverage vary by country)

What pricing and mix factors determine revenue trajectory?

Key drivers:

• Unit price compression after biosimilar launches and increased formulary tiering pressure
• Dose and persistence: insulin glargine is a chronic therapy; switching events are payer- and tolerability-driven
• Mix shift from 100 U/mL to U-300: Toujeo’s different concentration and dosing economics can preserve more revenue per patient in some contracts, depending on pricing
• Competitive substitution: once a biosimilar becomes the preferred basal insulin, switching from the reference product usually accelerates
• Rebate intensity and contracting: originators often protect share by trade-down pricing and rebate structures rather than headline list price

Which customer segments matter most financially?

• Commercial plans where step-therapy and formulary placement influence switching rate
• Government programs where tendering and reference pricing accelerate substitution
• Integrated provider systems where hospital outpatient insulin formularies drive consistent prescribing

What is the revenue trajectory for insulin glargine globally?

The trajectory for the insulin glargine franchise is best described as a progression:

1. Originator share and revenue dominance during early basal analog adoption
2. Plateau as biosimilar competition increases across major geographies
3. Continued revenue scale but margin compression as biosimilars gain share
4. Ongoing defense via U-300 differentiation, contracting, and line extension

The near-term outlook is shaped by incremental growth in the treated population, but the unit economics are increasingly set by biosimilar reference pricing.

What is the financial impact of switching from Lantus to Toujeo?

In markets where Toujeo is positioned as the preferred basal option, conversion to U-300 can:

• reduce reliance on 100 U/mL share
• maintain revenue intensity if contracts price U-300 more favorably than biosimilar-locked 100 U/mL products
• improve persistence if safety and hypoglycemia narratives (especially for nocturnal hypoglycemia) support payer acceptance

In markets where payers prefer biosimilar glargine 100 and treat Toujeo as “non-preferred,” conversion slows.

How do insulin glargine biosimilar launches change market dynamics?

Biosimilar dynamics are the core determinant of financial trajectory for glargine after the originator’s key exclusivities fade in each region.

What drives biosimilar uptake after launch?

• Automatic substitution policies (where permitted)
• Formulary placement: preference tier and step therapy rules
• Pricing-to-benchmark: biosimilars typically price below reference, but realized net depends on rebates
• Switching policies: prescriber willingness and payer directives
• Tender and competitive bidding in public systems

What risks do biosimilar entrants face that can slow revenue capture?

• Manufacturing scale-up and supply reliability
• Local interchangeability rules and naming constraints
• Payer skepticism and prescriber education requirements
• Tender structure where incumbents retain a share via rebate concessions

What is the market impact of multiple biosimilars competing for the same “basal glargine” shelf?

When more than one biosimilar is on-formulary, net price often compresses further and the originator’s remaining revenue increasingly depends on:

• premium positioning for U-300 (Toujeo)
• aggressive rebate strategies to offset biosimilar price gaps
• patient-level switching for outcomes or stability narratives

When does insulin glargine lose exclusivity and what does that mean financially?

Exclusivity timing is jurisdiction-specific and includes patent term and regulatory exclusivity. The financial effect is usually delayed relative to patent expiry because:

• switching cycles follow formulary contracting timelines
• payer adoption is staggered across plan types and geographic regions
• biosimilar uptake ramps after sufficient supply and prescriber comfort

What patent estate features matter for revenue protection?

For insulin glargine franchises, revenue protection is typically supported by:

• composition and formulation patent coverage (including different concentrations)
• process and manufacturing method claims
• device or delivery system IP (where applicable)
• method-of-use patents (in certain strategies)
• regulatory exclusivity anchored to the reference product pathway

What patents protect insulin glargine products, and how do they shape competition?

For a complete patent estate mapping, the specific reference product, formulation (100 U/mL vs U-300), and jurisdiction must be distinguished. Patent scope can differ materially by country, and “insulin glargine” commercial umbrella spans multiple distinct IP clusters.

How are different insulin glargine products separated in IP?

• Insulin glargine 100 U/mL: typically tied to the originator’s core formulation and manufacturing claims, plus delivery system IP depending on market
• Insulin glargine U-300 (Toujeo): often protected by additional patents around concentration-specific formulation and dosing characteristics
• Biosimilars: commonly challenge reference product patents through Paragraph IV-style approaches in the US biosimilar context, and via litigation in parallel EU and national systems

What is the FDA regulatory status of insulin glargine and its biosimilars?

In the US, insulin glargine products are governed by the biologics regulatory framework for originators and the biosimilar pathways for follow-on products. FDA status determines label access and interchangeability eligibility, which affects substitution behavior in pharmacies and formulary decisions in practice.

How does FDA labeling influence market share?

• Indication breadth and dosing regimens influence physician adoption
• Switching and substitution practices depend on label similarity and, where applicable, interchangeability determinations
• Safety and immunogenicity monitoring language can affect prescriber comfort in early adoption phases

Which insulin glargine biosimilars are challenging the market and where?

Biosimilar product presence and naming vary by geography. Financial impact depends on whether the biosimilar is placed on formulary as preferred, and whether it is subject to tendering or reference pricing.

What geographic patterns typically drive share gains?

• US: uptake tends to follow payer contracting and pharmacy channel adoption after biosimilar availability and physician education
• EU: market penetration often accelerates where national reimbursement policies support interchangeability-like behavior
• UK and other tendering systems: share can jump after procurement cycles

How does Toujeo (insulin glargine U-300) compare with glargine 100 in financial terms?

Toujeo’s financial role is to defend basal insulin revenue by:

• maintaining a differentiated positioning even as glargine 100 faces biosimilar substitution
• leveraging dosing characteristics to support payer acceptance where outcomes and hypoglycemia narratives support contracting

What matters most for Toujeo vs glargine 100 competition?

• Relative net price vs biosimilar glargine 100 under contract
• Formulary preference and step edits
• Clinical and safety narratives that affect prescriber and payer trust
• Patient switching friction and conversion rates

What patent litigation affects insulin glargine competition?

Patent litigation typically shapes timing by:

• delaying biosimilar commercial launch until resolution or settlement
• narrowing available launch pathways or triggering design-around changes
• setting settlement terms that can include market-entry dates, licensing fees, or exclusivity payments

What settlement dynamics are common in biosimilar insulin cases?

Settlements often trade litigation risk for predictable entry timelines. Financially, settlements can:

• preserve originator revenue longer than expected
• alter the speed of price compression
• affect the number and timing of biosimilar launches in a given market

How much market risk exists for originator insulin glargine revenue from generic or biosimilar substitution?

Because insulin glargine is a biologic, the relevant substitute category is biosimilars rather than “small-molecule” generics. Market risk is high where:

• reference product exclusivity has expired
• biosimilar products are approved and available with sufficient supply
• payers place biosimilars on preferred tiers with automatic substitution-like policies

Market risk is lower where:

• originator retains preferred tier through rebates and contracting
• U-300 differentiated product holds position in formularies
• switching requires administrative steps or prescriber re-authorization

What are the commercial levers originators use to defend insulin glargine revenue?

• Contracting: rebate and performance-based agreements
• Product strategy: push U-300 conversion, patient education, and persistence support
• Channel management: pharmacy and distributor incentives
• Evidence generation: continued clinical and real-world evidence to support payer decisions
• Supply reliability: ensuring biosimilar substitution does not coincide with shortages

Key Takeaways

• Insulin glargine’s financial trajectory is driven primarily by biosimilar uptake and payer contracting, not by new product creation.
• Revenue is increasingly maintained through mix shift toward U-300 (Toujeo), rebate strategy, and formulary defense as biosimilar glargine 100 gains share.
• Exclusivity and patent estates are jurisdiction-specific; the financial impact shows up through plan-by-plan switching timelines.
• Litigation and settlements affect the timing and speed of price compression, which is the core determinant of margin and revenue in the basal insulin market.
• The next major step-change in financial trajectory occurs when preferred formulary placement and substitution policies fully consolidate around biosimilars.

FAQs

How quickly do payers switch patients from Lantus to glargine biosimilars after launch?

Switch rates depend on formulary tiering, step therapy edits, tendering rules in public systems, and prescriber inertia. Where biosimilar is preferred, switching usually accelerates over subsequent contract cycles.

Does Toujeo lose share to glargine biosimilars?

Toujeo share can hold up or erode depending on net pricing versus preferred biosimilar 100 products, and on whether payers keep U-300 as a preferred option.

What is the biggest financial driver: unit price or volume?

In mature glargine, unit price compression from biosimilar competition is typically the dominant driver, with volume changes second and often governed by persistence and switching cycles.

Which market is usually hardest for originators to defend after biosimilar entry?

Markets with tendering and aggressive reference pricing tend to compress margins quickly and reduce originator formulary leverage.

Do insulin glargine delivery devices affect biosimilar competition?

Device and administration convenience can influence prescriber and patient preference, but interchangeability behavior is mostly determined by reimbursement policy and net pricing.

References

No sources were provided in the prompt, and no inline citations are included.